Stock events for Savara, Inc. (SVRA)
Savara's stock experienced several significant events over the past six months. In December 2025, the stock reached a 52-week high, and the company resubmitted its BLA for MOLBREEVI to the FDA. In February 2026, the FDA filed the MOLBREEVI BLA, granting it Priority Review with a PDUFA target action date of August 22, 2026, and Savara amended its loan agreement with Hercules Capital. In March 2026, Savara received a Day 74 Letter from the FDA, indicating that an Advisory Committee meeting is not planned for the MOLBREEVI BLA, and the company submitted a Marketing Authorization Application (MAA) to the EMA for MOLBREEVI. The stock price surged by 133.47% from March 4, 2025, to March 3, 2026, and 111% over the past year as of March 6, 2026.
Demand Seasonality affecting Savara, Inc.’s stock price
As a clinical-stage biopharmaceutical company, Savara, Inc. is currently focused on the research, development, and regulatory approval of MOLBREEVI. Therefore, there is no commercial product demand to assess for seasonality at this time. The company's financial performance and market interest are primarily driven by clinical trial progress and regulatory milestones rather than seasonal consumer demand.
Overview of Savara, Inc.’s business
Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Their primary product, MOLBREEVI, is in Phase 3 development for autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP), a rare lung disease with no approved treatments in the U.S. or Europe. The therapy is delivered via a proprietary eFlow® Nebulizer System, and Savara also offers the aPAP ClearPath antibody test, which has been launched in Europe.
SVRA’s Geographic footprint
Savara, Inc. is headquartered in Langhorne, Pennsylvania, United States. They are pursuing regulatory approvals for MOLBREEVI in the U.S., Europe, and the U.K. Market development efforts for MOLBREEVI are underway in Europe, with identified aPAP Centers of Excellence in countries including Germany, the UK, France, Italy, and Spain.
SVRA Corporate Image Assessment
Savara's brand reputation has been shaped by the progress of MOLBREEVI. The company benefits from a generally positive outlook from analysts, with a consensus recommendation of "Buy". Key positive events include the FDA granting Priority Review and setting a PDUFA date for MOLBREEVI, as well as the successful resubmission of the BLA. However, Savara faces inherent risks as a clinical-stage biopharmaceutical company, including potential regulatory setbacks, complexities in manufacturing, and the limited market size due to the rarity of autoimmune PAP.
Ownership
Savara Inc.'s ownership is primarily institutional, with nearly 90% of shares held by institutional investors including NEA Management Company, LLC, Bain Capital Life Sciences Investors, LLC, VR Adviser, LLC, Deerfield Management Company, L.p. (series C), BlackRock, Inc., Vanguard Group Inc, Frazier Life Sciences Management, L.P., Polar Capital Holdings Plc, Nantahala Capital Management, LLC, and Rtw Investments, Lp. Insider ownership stands at approximately 12.06%. James N. Topper is noted as owning the most shares among individual investors.
